Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
23,031.60
(
-2.05%
)
Dow Jones
45,960.11
(
-1.01%
)
Brent Oil
102.33
(
1.65%
)
Bitcoin
68,648.00
(
-0.20%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: WorstLuck post# 194470

Wednesday, 02/10/2016 12:46:20 PM

Wednesday, February 10, 2016 12:46:20 PM

Post# of 257295
(ENTA)—ABBV still hasn’t used its FDA priority review voucher purchased for $350M in Aug 2015 (#msg-116321586). IMO, it’s becoming more and more likely ABBV will use it for the ABT-493/ABT-530 pan-genotypic HCV regimen, which has six phase-3 trials in progress (#msg-119900756).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today